Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-05-30
2008-09-09
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S153100, C424S154100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388730, C530S388750
Reexamination Certificate
active
07422744
ABSTRACT:
The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αvβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain polypeptides and functional fragments. The LM609 grafted antibody consists of at least one CDR grafted heavy chain polypeptide and at least one CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding Vitaxin and LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of αvβ3. The method consists of contacting αvβ3with Vitaxin or a LM609 grafted antibody or functional fragments thereof under conditions which allow binding to αvβ3. Finally, the invention provides for a method of treating an αvβ3-mediated disease. The method consists of administering an effective amount of Vitaxin or a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to αvβ3.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5264563 (1993-11-01), Huse
patent: 5523388 (1996-06-01), Huse
patent: 5578704 (1996-11-01), Kim et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6531580 (2003-03-01), Huse et al.
patent: 6590079 (2003-07-01), Huse et al.
patent: 6887473 (2005-05-01), Brooks et al.
patent: 0 451 216 (1991-10-01), None
patent: 0 682040 (1995-11-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 96/40250 (1996-12-01), None
patent: WO 98/33919 (1998-08-01), None
Webster's II New Riverside University Dictionary, The Riverside Publishing Company, Boston, 1994; p. 385.
Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition (W.B. Saunders Company, Philadelphia, 1981; p. 385.
Illustrated Stedman's Medical Dictionary 24th Edition, Williams & Wilkins, Baltimore, 1982; p. 403.
Adams et al., “Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies,”Cancer Res., 58:485-490 (1998).
Alfthan,Biosensors and Bioelectronics, “Surface plasmon resonance biosensors as a tool in antibody engineering,” 13:653-663 (1998).
Beidler C., “Mammalian expression and characterization of a dimeric single chain antibody specific for integrin alpha-v-beta-3,”Immunotechnologyvol. 2 p. 297 (1996).
Biotechnology Newswatch, pp. 11-12, Jan. 16, 1995.
Biotechnology Newswatch, pp. 11, Feb. 6, 1995.
Brooks et al., “Integrin -ανβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,”Cell79:1157-1164 (1994).
Carmeliet, P., “Integrin indecision,”Nature Medicine8:14-16 (2002).
Cheresh, D.A., “Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved n attachment to fibrinogen and von Willebrand factor,”Proc. Natl. Acad. Sci. USA84:6471-6475 (1987).
Cheresh and Spiro, “Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor,”J. Biol. Chem.262(36):17703-17711 (1987).
Cheresh and Stupack, “Integrin-mediated death: An explanation of the integrin-knockout phenotype,”Nature Medicine8:193-194 (2002).
Choi et al., “Inhibition of neointimal hypersplasia by blocking -ανβ3integrin with a small peptide antagonist GpenGRGDSPCA,” J. Vascular Surg., 19:125-134 (1994).
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol.196:901-917 (1987).
Chowdhury et al., “Improving antibody affinity by mimicking somatic hypermutation in vitro,”Nature Biotech17:568-572 (1999).
Clark, M. (ed.), “Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man,” Nottingham, England: Academic Titles (1993).
Davies and Riechmann, “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,”Immunotechnology2:169-179 (1996).
Day, E.D.,Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990).
Devlin et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,”Science249:404-406, (1990).
Dueñas et al., “selection of phage displayed antibodies based on kinetic constants,”Molec. Immunol., 33(3):279-285 (1996).
Foote and Milstein, “Kinetic maturation of an immune response,”Nature352:530-532 (1991).
Glaser et al., “Antibody Engineering by Condon-Based Mutagenesis in a Filamentous Phage Vector System,”J. Immunol.149:3903-3913 (1992).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity, Mimicking Affinity Maturation,”J. Mol. Biol., 226:889-896 (1992).
Huse, W.D., “Combinatorial Antibody Expression Libraries in Filamentous Phage,” In: Antibody Engineering: A Practical Guide, C.A.K. Borrebaeck, ed. W.H. Freeman and Co., Publishers, New York, pp. 103-120 (1991).
Huse et al., “Applications of a Filamentous Phage pVIII Fusion Protein System Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments,”J. Immunol.149:3914-3920 (1992).
Huston et al., “Antigen Recognition and Targeted Delivery by the Single-Chain Fv,”Cell Biophysics, 22:189-224 (1993).
Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest,” vol. 1 (1991).
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,”J. Mol. Biol.262:732-745 (1996).
Moore et al., “Directed evolution ofpara-nitrobenzyl esterase for aqueous-organic solvents,”Nature Biotechnology14:458-467 (1996).
Myszka et al., “Kinetic analysis of a protein-antibody interaction limited by mass transportation on an optical biosensor,”Biophys. Chem., 64:127-137 (1997).
Newman et al., ““Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4,”Biotechnol., 10:1455-1460 (1992).
Padlan, Eduardo A., “A Possible Procedure For Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties,”Molecular Immunol.28(4/5):489-498 (1991).
Posey et al., “A Pilot Trial of Vitazin, A Humanized Anti-Vitronection Receptor (anti ανβ3) Antibody in Patients with Metastic Cancer,”Cancer Biotherapy&Radiopharmaceuticals16:125-132 (2001).
Plückthun and Skerra, “Expression of functional antibody Fv and Fab fragments inEscherichia coli,” Meth. Enzymol.178:497-515 (1989).
Rader et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,”Proc. Natl. Acad. Sci. USA, 95:8910-8915 (1998).
Reynolds et al., “Enhanced pathological angiogenesis in mice lacking β3integrin or β3and β5integrins,”Nature Medicine8:27-34 (2002).
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,”J. Biol. Chem.271:22611-22618 (1996).
Sandberg and Terwilliger, “Engineering multiple properties of a protein by combinatorial mutagenesis,”Proc. Natl. Acad. Sci.90:8367-8371 (1993).
Schier et al., “Isolation of Picomo
Glaser Scott M
Huse William D
Applied Molecular Evolution, Inc.
Gambel Phillip
McDermott Will & Emery LLP
LandOfFree
Methods of treating cancer with alphavbeta3-specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cancer with alphavbeta3-specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer with alphavbeta3-specific antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991775